Shares of Galapagos NV (NASDAQ:GLPG) have been given an average rating of “Buy” by the nine research firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $99.20.
A number of equities analysts recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research report on Wednesday, July 26th. Zacks Investment Research upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Friday, July 14th. Janney Montgomery Scott upgraded shares of Galapagos NV from a “sell” rating to a “neutral” rating in a research report on Friday, July 7th. They noted that the move was a valuation call. Instinet reiterated a “buy” rating and issued a $108.00 price objective (down from $121.00) on shares of Galapagos NV in a research report on Thursday, June 22nd. Finally, TheStreet upgraded shares of Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th.
Galapagos NV (NASDAQ GLPG) traded down 1.27% during trading on Monday, hitting $77.01. 98,470 shares of the company traded hands. The firm’s market capitalization is $3.92 billion. Galapagos NV has a 52-week low of $51.91 and a 52-week high of $94.88.
A number of large investors have recently added to or reduced their stakes in GLPG. UBS Group AG increased its stake in Galapagos NV by 237.0% in the first quarter. UBS Group AG now owns 3,522 shares of the biotechnology company’s stock worth $303,000 after buying an additional 2,477 shares during the period. Cim Investment Mangement Inc. acquired a new stake in Galapagos NV during the first quarter worth approximately $203,000. Marshall Wace North America L.P. acquired a new stake in Galapagos NV during the first quarter worth approximately $989,000. MARSHALL WACE ASIA Ltd acquired a new stake in Galapagos NV during the first quarter worth approximately $989,000. Finally, Bogle Investment Management L P DE acquired a new stake in Galapagos NV during the first quarter worth approximately $368,000. 19.98% of the stock is owned by institutional investors.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://stocknewstimes.com/2017/08/03/galapagos-nv-nasdaqglpg-receives-average-recommendation-of-buy-from-analysts-updated.html.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.
